Clinical Efficacy and Molecular Response Correlates of the WEE1 Inhibitor Adavosertib Combined with Cisplatin in Patients with Metastatic Triple-Negative Breast Cancer

Tanya E. Keenan; Tianyu Li; Tuulia Vallius; Jennifer L. Guerriero; Nabihah Tayob; Bose Kochupurakkal; Janae Davis; Ricardo Pastorello; Rie K. Tahara; Leilani Anderson; Jake R. Conway; Meng X. He; Erin Shannon; Robert Godin; Peter K. Sorger; Alan D. D’Andrea; Beth Overmoyer; Eric P. Winer; Elizabeth A. Mittendorf; Eliezer M. Van Allen; Geoffrey I. Shapiro; Sara M. Tolaney

doi:10.1158/1078-0432.ccr-20-3089

Abstract

Among patients with mTNBC treated with 0-1 prior lines, adavosertib combined with cisplatin missed the prespecified ORR cutoff of >30%. The finding of immune-infiltrated tumors in patients with clinical benefit warrants validation.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Keenan et al. (2020) studied this question.

synapsesocial.com/papers/69d7793f3fae90fd6048f3e5 https://doi.org/10.1158/1078-0432.ccr-20-3089

View Full Paper

Ask AI

Bookmark

Share

Clinical Efficacy and Molecular Response Correlates of the WEE1 Inhibitor Adavosertib Combined with Cisplatin in Patients with Metastatic Triple-Negative Breast Cancer

Abstract

Discussion

Cite This Study

Clinical Efficacy and Molecular Response Correlates of the WEE1 Inhibitor Adavosertib Combined with Cisplatin in Patients with Metastatic Triple-Negative Breast Cancer

Abstract

Discussion

Cite This Study

Keep reading

Keep reading